Portal vein thrombosis in cirrhosis: Controversies and latest developments

Table 3 Summary of new oral anti-coagulants

Name	Dabigatran	Apixaban	Edoxaban	Rivaroxaban
Action	Direct thrombin inhibitor	Activated factor Xa inhibitor	Activated factor Xa inhibitor	Activated factor Xa inhibitor
Clearance	80% renal clearance	73% hepatic	50% hepatic	65% hepatic
		27% renal clearance	50% renal clearance	35% renal clearance
CYP3A4 interaction?	No	Yes (minor)	Minimal	Yes
Absorption with food?	No effect	No effect	Up to 20% more	40% more therefore intake with food
Elimination half life	12-17 h	12 h	9-11 h	8-9 h young
				11-13 h elderly